Log In
Print
BCIQ
Print
Print this Print this
 

Polatuzumab vedotin (DCDS4501A, RG7596)

  Manage Alerts
Collapse Summary General Information
Company Genentech Inc.
DescriptionAntibody-drug conjugate (ADC) composed of an anti-CD79B mAb and monomethyl auristatin E (MMAE)
Molecular Target CD79b molecule immunoglobulin-associated beta (CD79B) (B29)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today